Inflammatory breast cancer (IBC) is rare and accounts for only 1% to 5% of all breast cancers, but it is considered an aggressive cancer because it grows quickly and is more likely to come back after treatment than other types of breast cancer. It causes symptoms of breast inflammation like swelling and redness, which is caused by cancer cells blocking lymph vessels in the skin causing the breast to look "inflamed."
Gayathri R. Devi, PhD, is a two-time American Cancer Society grantee who recently received a Mission Boost Grant to “boost” her inflammatory breast cancer research and move it closer to patients.
Dr. Devi joined the podcast to talk about risk factors for IBC, how it’s different from other breast cancer types, and recent advances in her lab with promising clinical implications.
Dr. Devi is Program Director for the Duke Consortium for Inflammatory Breast Cancer, Associate Professor of Surgery and Pathology at Duke School of Medicine, and the Director of the Duke North Carolina Central University bridge office as part of the Duke School of Medicine Clinical and Translational Sciences Institute.
3:18 – The symptoms and signs of inflammatory breast cancer (IBC)
6:34 – How inflammatory breast cancer differs from other, more common breast cancers
9:36 – Risk factors for inflammatory breast cancer
14:22 –Instead of a single tumor mass, IBC patients have small groups of tumor cells called emboli found in the breast, skin and lymph nodes around the breast tissue. What are emboli? How do they form?
16:00 – Why do emboli form in this way?
18:51 – What makes these emboli resistant to treatment and able to spread?
21:43 – On her ACS-funded research, which focuses on the environment in which the IBC emboli form, in the breast. Why is the breast environment so important?
28:35 – Adaptive stress response
31:15 – “I’ll give you an example here and talk a little about our research findings that are clinically relevant.”
38:25 – How do we target inflammatory breast cancer therapeutically?
40:47 – The 3M approach: Models, Mechanisms, and Measures
45:30 – If she could wave a magic anti-IBC wand, where would we be in 5 years?
48:27 – The impact that ACS funding has had on this area of research
49:54 – “Another very important distinction about ACS…”
51:47 – How inflammatory breast cancer recently affected her family
All content for TheoryLab is the property of American Cancer Society and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Inflammatory breast cancer (IBC) is rare and accounts for only 1% to 5% of all breast cancers, but it is considered an aggressive cancer because it grows quickly and is more likely to come back after treatment than other types of breast cancer. It causes symptoms of breast inflammation like swelling and redness, which is caused by cancer cells blocking lymph vessels in the skin causing the breast to look "inflamed."
Gayathri R. Devi, PhD, is a two-time American Cancer Society grantee who recently received a Mission Boost Grant to “boost” her inflammatory breast cancer research and move it closer to patients.
Dr. Devi joined the podcast to talk about risk factors for IBC, how it’s different from other breast cancer types, and recent advances in her lab with promising clinical implications.
Dr. Devi is Program Director for the Duke Consortium for Inflammatory Breast Cancer, Associate Professor of Surgery and Pathology at Duke School of Medicine, and the Director of the Duke North Carolina Central University bridge office as part of the Duke School of Medicine Clinical and Translational Sciences Institute.
3:18 – The symptoms and signs of inflammatory breast cancer (IBC)
6:34 – How inflammatory breast cancer differs from other, more common breast cancers
9:36 – Risk factors for inflammatory breast cancer
14:22 –Instead of a single tumor mass, IBC patients have small groups of tumor cells called emboli found in the breast, skin and lymph nodes around the breast tissue. What are emboli? How do they form?
16:00 – Why do emboli form in this way?
18:51 – What makes these emboli resistant to treatment and able to spread?
21:43 – On her ACS-funded research, which focuses on the environment in which the IBC emboli form, in the breast. Why is the breast environment so important?
28:35 – Adaptive stress response
31:15 – “I’ll give you an example here and talk a little about our research findings that are clinically relevant.”
38:25 – How do we target inflammatory breast cancer therapeutically?
40:47 – The 3M approach: Models, Mechanisms, and Measures
45:30 – If she could wave a magic anti-IBC wand, where would we be in 5 years?
48:27 – The impact that ACS funding has had on this area of research
49:54 – “Another very important distinction about ACS…”
51:47 – How inflammatory breast cancer recently affected her family
People going through cancer treatment sometimes have cognitive changes such as trouble remembering, paying attention, or thinking clearly.
Drs. Judith Carroll and Kathleen Van Dyk are clinician scientists who help patients with cancer-related cognitive impairment and conduct research into what causes it, how to identify patients at risk for it, and how to reverse its effects.
Judith Carroll, PhD, is Associate Professor in the Department of Psychiatry and Biobehavioral Science at the Jane and Terry Semel Institute for Neuroscience and Human Behavior at UCLA, and she’s the term Endowed Chair of the George F. Solomon Professorship in Psychobiology at UCLA. She’s also a Member of the Cousins Center for Psychoneuroimmunology. She received American Cancer Society funding to support her research on “Biobehavioral Vulnerability to Accelerated Aging In Breast Cancer Survivors” from 2016-2020.
Kathleen Van Dyk, PhD, is Assistant Professor in the Department of Psychiatry and Biobehavioral Science at the Jane and Terry Semel Institute for Neuroscience and Human Behavior at UCLA, and she’s a practicing neuropsychologist. She was an American Cancer Society postdoctoral fellow, studying “Cognitive Decline in Breast Cancer Survivors,” from 2017-2019.
INCIDENCE AND NATURE OF THE PROBLEM
2:09 – What is “cancer-related cognitive impairment?” Is it the same as “chemo brain?”
3:12 – How common is it?
4:41 – What kind of symptoms does it produce?
CONTRIBUTING FACTORS AND MECHANISMS
6:54 – Is cancer-related cognitive impairment a side effect of cancer? Is it caused by certain treatments?
12:11 – How has COVID impacted cognitive impairment among breast cancer survivors?
14:22 – On the biology of aging and how cancer could accelerate the aging process
TREATMENT
17:48 – Is cancer-related cognitive impairment reversible?
22:04 – On the exciting potential of sleep interventions
23:54 – Understanding the effects of endocrine therapies on brain function
CLOSING THOUGHTS
25:42 – How ACS funding has impacted their career and research
29:40 – A message they’d like to share with cancer patients, survivors, and caregivers who are concerned about cancer-related cognitive impairment
TheoryLab
Inflammatory breast cancer (IBC) is rare and accounts for only 1% to 5% of all breast cancers, but it is considered an aggressive cancer because it grows quickly and is more likely to come back after treatment than other types of breast cancer. It causes symptoms of breast inflammation like swelling and redness, which is caused by cancer cells blocking lymph vessels in the skin causing the breast to look "inflamed."
Gayathri R. Devi, PhD, is a two-time American Cancer Society grantee who recently received a Mission Boost Grant to “boost” her inflammatory breast cancer research and move it closer to patients.
Dr. Devi joined the podcast to talk about risk factors for IBC, how it’s different from other breast cancer types, and recent advances in her lab with promising clinical implications.
Dr. Devi is Program Director for the Duke Consortium for Inflammatory Breast Cancer, Associate Professor of Surgery and Pathology at Duke School of Medicine, and the Director of the Duke North Carolina Central University bridge office as part of the Duke School of Medicine Clinical and Translational Sciences Institute.
3:18 – The symptoms and signs of inflammatory breast cancer (IBC)
6:34 – How inflammatory breast cancer differs from other, more common breast cancers
9:36 – Risk factors for inflammatory breast cancer
14:22 –Instead of a single tumor mass, IBC patients have small groups of tumor cells called emboli found in the breast, skin and lymph nodes around the breast tissue. What are emboli? How do they form?
16:00 – Why do emboli form in this way?
18:51 – What makes these emboli resistant to treatment and able to spread?
21:43 – On her ACS-funded research, which focuses on the environment in which the IBC emboli form, in the breast. Why is the breast environment so important?
28:35 – Adaptive stress response
31:15 – “I’ll give you an example here and talk a little about our research findings that are clinically relevant.”
38:25 – How do we target inflammatory breast cancer therapeutically?
40:47 – The 3M approach: Models, Mechanisms, and Measures
45:30 – If she could wave a magic anti-IBC wand, where would we be in 5 years?
48:27 – The impact that ACS funding has had on this area of research
49:54 – “Another very important distinction about ACS…”
51:47 – How inflammatory breast cancer recently affected her family
